A Phase 4 interventional study of Bevacizumab and Triamcinolone Acetonide in Keloids, sponsored by Kasr El Aini Hospital. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Kasr El Aini Hospital · Phase 4, Interventional, and Treatment
The study compares the efficacy and safety of intralesional bevacizumab versus corticosteroids for the treatment of keloids. Assessment will be done clinically by the use of Modified Vancouver Scar Scale. Erythema index will be measured by spectrophotometry. The levels of Vascular Endothelial Growth Factor, collagen type 1 and collagen type 3 in the lesions before and after each treatment modality.
138 studies on the registry are indexed under Keloid; 26 are open to participants now.
This study's enrollment of 28 is close to the median of 30 across 109 interventional studies indexed under Keloid.
Browse Keloid studies →Kasr El Aini Hospital is the lead sponsor of 287 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intralesional bevacizumab injection for the treatment of keloid
Drug: Bevacizumab
Intralesional triamcinolone acetonide injection for the treatment of keloids
Drug: Triamcinolone Acetonide
anti-VEGF
corticosteroid
Modified Vancouver scar scale (mVSS)
Six characteristics of the scar were assessed. These are: vascularity, height, pliability, and pigmentation, pain and pruritis. Each characteristic is given a score, which are added together to give an overall score between 0 and 18. Higher scores mean a worse outcome.
Time frame: 6 months
Erythema Index
Evaluation of skin erythema index was done using a spectrophotometry device
Time frame: 6 months
Vascular Endothelial growth factor (VEGF)
Tissue levels of VEGF, collagen type 1 and 3 measured by Enzyme linked immunosorbent assay
Time frame: 6 months
Collagen type 1 and 3
Tissue levels of collagen type 1 and 3 measured by Enzyme linked immunosorbent assay
Time frame: 6 months
Histopathological examination
Two mm punch biopsies were obtained per area at baseline and one month after the last treatment session. The post-treatment biopsy 3as taken from the vicinity of the baseline biopsy. Tissues are fixed in 10% buffered formalin, embedded in paraffin and sectioned into 5 μm-thick sections. Specimens were stained with hematoxylin and eosin (H\&E) and orcein (or demonstration of elastic fibers). Histological examination was carried out under a light microscopy. Assessment was done as follows: 1. Assessment of the collagen fibers will be done by examining H \& E slides, putting grading from 1 to 4 according to the thickness and orientation of the collagen fibers and the spaces in between the fibers. 2. Assessment of the elastic fibers will be done through examining orcein stained specimens and grading the elastic fibers in the scars from 1 to 4 based on presence or absence of the elastic fiber and degree of degradation and fragmentation.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Sep 2024, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Triamcinolone Acetonide